Valence-Logo
Beliebt
Anmelden
Loading data for ERAS — first visit, this takes a few seconds.

Zur Watchlist hinzufügen

Erasca Inc.

NasdaqGS: ERAS · Echtzeitkurs · USD
18.10
-0.18 (-0.98%)
Zum Schluss: Aug 18, 2026, 3:59 PM

Erasca Inc. (ERAS) Stock Price, Analysis & Data

-0.98%
Geld13.27
Marktkapitalisierung6.31 Mrd
Umsatz (TTM)n/a
Nettogewinn (TTM)-287.22 Mio
Beta0.65
EPS (ttm)-0.95
KGV (TTM)n/a
Forward-KGV-31.02
KBV (TTM)15.59
KUV (TTM)n/a
Earnings DateNov 11, 2026
Brief23
Volumen1,830,092
Ø Vol. (20D)4,923,824
Eröffnung18.19
Vortagesschluss18.28
Tagesspanne17.85 - 18.72
52-Wk Range1.33 - 24.28
Analystn/a
Kurszieln/a
Dividendenn/a
Ex-Dividenden-Datumn/a

Über ERAS

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 ...

[Mehr lesen]
Branche Biotechnology
Sektor Healthcare
IPO Datum Jul 16, 2021
Mitarbeiter 103
Börse NasdaqGS
Tickersymbol ERAS
Website https://www.erasca.com
Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Erasca 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -124.55 Mio, ein Rückgang von -22.95 %.

Finanzberichte

Gewinnüberraschung

Erasca hat die Quartalszahlen am Aug 11, 2026 veröffentlicht:
  • Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.
  • EPS von -0.14 verfehlt die Erwartungen um -0.03, mit -16.67% Rückgang im Jahresvergleich.

    • Nächste Ergebnisveröffentlichung

    Erasca Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 11, 2026, während der Handelszeiten.
    Analysten erwarten einen Umsatz von ... Upgrade
    news image

    vor 1 Monat · Simply Wall St.

    Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

    Erasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this...

    news image

    vor 1 Monat · Simply Wall St.

    Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?

    Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a ...

    news image

    vor 1 Monat · Simply Wall St.

    Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers

    Erasca recently reported updated preliminary Phase 1 data for its oral pan-RAS molecular glue ERAS-0015, showing encouraging responses and a generally well-tolerated safety profile in RAS-mutant solid...

    news image

    vor 1 Monat · Insider Monkey

    Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

    Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, stre...

    news image

    vor 1 Monat · Barrons.com

    Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ List

    Robinhood Markets is added as a top stock for July. Micron and Oracle are among Mizuho Securities’ top picks for the month.

    Seite 1 von 2